- Home
- NPCT vs EBS Comparison
NPCT vs EBS Comparison
Compare NPCT & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- EBS
- Stock Information
- Founded
- NPCT 2020
- EBS 1998
- Country
- NPCT United States
- EBS United States
- Employees
- NPCT N/A
- EBS N/A
- Industry
- NPCT Investment Managers
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- EBS Health Care
- Exchange
- NPCT Nasdaq
- EBS Nasdaq
- Market Cap
- NPCT 316.0M
- EBS 359.3M
- IPO Year
- NPCT N/A
- EBS 2006
- Fundamental
- Price
- NPCT $10.81
- EBS $7.16
- Analyst Decision
- NPCT
- EBS Strong Buy
- Analyst Count
- NPCT 0
- EBS 3
- Target Price
- NPCT N/A
- EBS $14.33
- AVG Volume (30 Days)
- NPCT 107.1K
- EBS 1.4M
- Earning Date
- NPCT 01-01-0001
- EBS 08-06-2025
- Dividend Yield
- NPCT 9.82%
- EBS N/A
- EPS Growth
- NPCT N/A
- EBS N/A
- EPS
- NPCT N/A
- EBS N/A
- Revenue
- NPCT N/A
- EBS $965,400,000.00
- Revenue This Year
- NPCT N/A
- EBS N/A
- Revenue Next Year
- NPCT N/A
- EBS $16.15
- P/E Ratio
- NPCT N/A
- EBS N/A
- Revenue Growth
- NPCT N/A
- EBS N/A
- 52 Week Low
- NPCT $8.58
- EBS $4.02
- 52 Week High
- NPCT $10.63
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- NPCT 43.79
- EBS 53.48
- Support Level
- NPCT $10.80
- EBS $6.89
- Resistance Level
- NPCT $11.11
- EBS $7.83
- Average True Range (ATR)
- NPCT 0.14
- EBS 0.37
- MACD
- NPCT -0.05
- EBS -0.00
- Stochastic Oscillator
- NPCT 17.31
- EBS 42.80
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.